Literature DB >> 28379450

Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment.

Sean E Lawler1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28379450      PMCID： PMC5464378          DOI： 10.1093/neuonc/nox011

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  9 in total

Review 1.  The Basis of Oncoimmunology.

Authors:  A Karolina Palucka; Lisa M Coussens
Journal:  Cell       Date:  2016-03-10       Impact factor: 41.582

2.  Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.

Authors:  Norman Woller; Engin Gürlevik; Bettina Fleischmann-Mundt; Anja Schumacher; Sarah Knocke; Arnold M Kloos; Michael Saborowski; Robert Geffers; Michael P Manns; Thomas C Wirth; Stefan Kubicka; Florian Kühnel
Journal:  Mol Ther       Date:  2015-06-26       Impact factor: 11.454

Review 3.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

4.  Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.

Authors:  Jayson Hardcastle; Lisa Mills; Courtney S Malo; Fang Jin; Cheyne Kurokawa; Hirosha Geekiyanage; Mark Schroeder; Jann Sarkaria; Aaron J Johnson; Evanthia Galanis
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 5.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

6.  Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

Authors:  Igor Puzanov; Mohammed M Milhem; David Minor; Omid Hamid; Ai Li; Lisa Chen; Michael Chastain; Kevin S Gorski; Abraham Anderson; Jeffrey Chou; Howard L Kaufman; Robert H I Andtbacka
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544

7.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

8.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

Authors:  Eric Bouffet; Valérie Larouche; Brittany B Campbell; Daniele Merico; Richard de Borja; Melyssa Aronson; Carol Durno; Joerg Krueger; Vanja Cabric; Vijay Ramaswamy; Nataliya Zhukova; Gary Mason; Roula Farah; Samina Afzal; Michal Yalon; Gideon Rechavi; Vanan Magimairajan; Michael F Walsh; Shlomi Constantini; Rina Dvir; Ronit Elhasid; Alyssa Reddy; Michael Osborn; Michael Sullivan; Jordan Hansford; Andrew Dodgshun; Nancy Klauber-Demore; Lindsay Peterson; Sunil Patel; Scott Lindhorst; Jeffrey Atkinson; Zane Cohen; Rachel Laframboise; Peter Dirks; Michael Taylor; David Malkin; Steffen Albrecht; Roy W R Dudley; Nada Jabado; Cynthia E Hawkins; Adam Shlien; Uri Tabori
Journal:  J Clin Oncol       Date:  2016-03-21       Impact factor: 44.544

9.  Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Authors:  Julia V Cockle; Karishma Rajani; Shane Zaidi; Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Kevin Shim; Tim Peterson; Ian F Parney; Susan Short; Peter Selby; Elizabeth Ilett; Alan Melcher; Richard Vile
Journal:  Neuro Oncol       Date:  2015-09-26       Impact factor: 12.300
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.